FDA extends Exelixis zanzalintinib review by three months

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. USO
6. AMD
7. TSLA
8. ACN
9. COHR
10. META

Go back to FDA extends Exelixis zanzalintinib review by three months
Exelixis, Inc. (NASDAQ: EXEL) Delayed: 57.22 --0 (-0%)
Previous Close $57.22    52 Week High $17.00 
Open $57.22    52 Week Low $3.55 
Day High $57.22    P/E N/A 
Day Low $57.22    EPS $-1.33 
Volume 13,005